Ignite Creation Date:
2024-05-06 @ 6:48 PM
Last Modification Date:
2024-10-26 @ 2:54 PM
Study NCT ID:
NCT05786521
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-07-11
First Post:
2023-03-02
Brief Title:
Effect of GLP1 Receptor Agonists on Physical Function Body Composition and Markers of Aging in Older Adults
Sponsor:
The University of Texas Health Science Center at San Antonio
Organization:
The University of Texas Health Science Center at San Antonio
Study Overview
Official Title:
The Effect of GLP1 Receptor Agonists on Physical Function Body Composition and Biomarkers of Aging in Older OverweightObese Adults With Insulin Resistance
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Semaglutide is a medication approved by the US Food and Drug Administration FDA as an antihyperglycemic a drug that reduces glucoses in those with diabetes and for weight management This new study will help find out what effects semaglutide has on people who take the drug and the drugs effect on physical function body composition and aging
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 5P30AG044271-08 | NIH | None | httpsreporternihgovquickSearch5P30AG044271-08 |